Keyword: Tonix Pharmaceuticals
Tonix Pharmaceuticals is licensing a phase 2 treatment for cocaine intoxication from Columbia University.
Tonix Pharmaceuticals has lost a U.S. Army agreement to develop TNX-102 SL in military-related post-traumatic stress disorder.
The biotech hit upon the upbeat interpretation by separating out the results from patients who suffered the trauma within the past nine years.
Tonix Pharmaceuticals has started recruiting military personnel into a phase 3 trial of its drug candidate for combat-related post-traumatic stress disorder (PTSD).